Artesunate Vaginal Inserts for Cervical Dysplasia (ART-CIN_IIB Trial)

"Yes. The clinical trial is recruiting for 78 patients across 8 locations, as indicated on the website clinicaltrials.gov. This information was last updated on 9/12/2022, and the trial was initially posted on 9/9/2020."

"Artesunate vaginal insert was first studied in the year 2017 at University Hospitals of Derby and Burton NHS Foundation Trust. Since then there have been 118 completed studies with 12 clinical trials currently recruiting patients. Many of these studies are being performed out of Ann Arbor, Michigan."

"The primary outcome of this trial, which will be measured over a 15 week time frame is the Proportion of participants with histologic regression by week 17. Secondary outcomes include: the Number of participants who have achieved clearance of detectable human papilloma virus (HPV) by week 17, defined as the Number of participants who had HPV strains detected at study entry which become undetectable by week 17; the Number of participants who have achieved clearance of detectable human papilloma virus (HPV) after three 5-day cycles of artesunate and the LEEP procedure, defined as the Number of participants who had HPV"

"That is correct. Based on the information available from clinicaltrials.gov, this specific trial is searching for patients and was last updated September 12th, 2022. They are looking for 78 people total across 8 sites."

"Although there is lack of data regarding Artesunate vaginal insert's efficacy, it has been determined to be safe in Phase 2 trials. Consequently, our team gives it a safety rating of 2."

"In order to participate in this clinical trial, applicants must be aged 25-100. There are a total of 34 studies for patients under 18 and 102 for those over 65 years old."

"Patients can enroll at 8 different locations including Ann Arbor, Brightwaters and Mayfield Heights. The other enrolment centres are located near these cities. If you decide to participate in this trial, try to select the closest location to minimize travel time and expenses."

"This study is recruiting 78 people with immunoglobulin g4-related disease between the ages of 25 and 100. Most notable, patients must meet the following criteria: Adult females age ≥ 25 years, Capable of informed consent, Colposcopically-directed, histologically confirmed tissue diagnosis of cervical high grade squamous intraepithelial lesions (CIN2, CIN3, or CIN2/3), Women of childbearing potential agree to use birth control through week 28 of the study., Weight ≥ 50kg, Any HPV genotype detectable by DNA test/HPV genotyping."